Akebia Therapeutics, Inc. (AKBA)
Company Info
| ISIN | US00972D1054 |
|---|---|
| CUSIP | 00972D105 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $306.01M |
|---|---|
| EPS (TTM) | -$0.22 |
| PE Ratio | 17.56 |
| Total Revenue (TTM) | $130.85M |
| Gross Profit (TTM) | $81.81M |
| EBITDA (TTM) | $1.77M |
| Year Range | $0.78 - $2.48 |
| Target Price | $5.00 |
| Short % | 6.32% |
| Short Ratio | 3.40 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Akebia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Akebia Therapeutics, Inc. had a return of 19.35% year-to-date (YTD) and 2.07% in the last 12 months. Over the past 10 years, Akebia Therapeutics, Inc. had an annualized return of -23.81%, while the S&P 500 had an annualized return of 10.58%, indicating that Akebia Therapeutics, Inc. did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 19.35% | 13.20% |
| 1 month | 72.76% | -1.28% |
| 6 months | -1.33% | 10.32% |
| 1 year | 2.07% | 18.23% |
| 5 years (annualized) | -17.61% | 12.31% |
| 10 years (annualized) | -23.81% | 10.58% |
Monthly Returns
The table below presents the monthly returns of AKBA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 35.48% | -5.95% | 15.82% | -31.15% | -11.11% | -8.93% | 19.35% | ||||||
| 2023 | 9.19% | 33.76% | -33.50% | 62.12% | 14.47% | -12.02% | 82.51% | -16.77% | -17.99% | -22.81% | 20.45% | 16.98% | 114.90% |
| 2022 | -11.95% | 8.54% | -66.76% | -42.16% | -10.91% | -4.54% | 10.73% | -6.83% | -13.20% | -19.51% | 6.29% | 113.31% | -74.47% |
| 2021 | 15.71% | 6.79% | -2.17% | -5.76% | 10.03% | 7.98% | -34.83% | 19.03% | -2.04% | -0.35% | -5.57% | -16.61% | -19.29% |
| 2020 | 14.24% | 22.85% | -14.54% | 6.86% | 43.70% | 16.67% | -17.75% | -6.80% | -75.89% | -11.55% | 49.10% | -15.41% | -55.70% |
| 2019 | -0.36% | 32.12% | 12.50% | -26.25% | -26.32% | 8.76% | -13.43% | -1.43% | -5.08% | -4.85% | 68.63% | 0.48% | 14.29% |
| 2018 | -0.61% | -3.25% | -33.36% | -3.36% | 6.62% | 1.63% | 3.21% | -20.29% | 7.55% | -15.18% | 7.88% | -31.56% | -62.81% |
| 2017 | -3.65% | -0.10% | -8.18% | 43.26% | 1.67% | 7.24% | -8.21% | 26.91% | 17.50% | -7.73% | -14.27% | -4.43% | 42.84% |
| 2016 | -43.27% | -0.41% | 23.42% | 4.22% | -5.11% | -16.05% | 19.65% | -9.16% | 11.32% | -16.91% | 14.49% | 20.91% | -19.43% |
| 2015 | -11.77% | -9.83% | 19.98% | -30.96% | 2.48% | 30.92% | -8.65% | -25.96% | 38.79% | -7.66% | 20.29% | 20.41% | 11.00% |
| 2014 | -26.73% | 24.59% | -0.29% | 14.36% | -20.33% | 1.67% | -1.69% | -41.44% | -6.79% | -3.64% | -56.40% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of AKBA is 50, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Akebia Therapeutics, Inc. (AKBA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Akebia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Akebia Therapeutics, Inc. was 99.14%, occurring on Nov 29, 2022. The portfolio has not yet recovered.
The current Akebia Therapeutics, Inc. drawdown is 94.93%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.14% | Jun 23, 2014 | 2126 | Nov 29, 2022 | — | — | — |
| -36.84% | Mar 21, 2014 | 16 | Apr 11, 2014 | 5 | Apr 21, 2014 | 21 |
| -21.82% | Apr 22, 2014 | 20 | May 19, 2014 | 14 | Jun 9, 2014 | 34 |
| -4.91% | Jun 10, 2014 | 6 | Jun 17, 2014 | 3 | Jun 20, 2014 | 9 |
Volatility
Volatility Chart
The current Akebia Therapeutics, Inc. volatility is 22.89%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
P/E Ratio
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Akebia Therapeutics, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |